Álvaro Girón-Martínez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Álvaro Girón-Martínez has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Sandra Pérez-Rial
Respiratory Research Group, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz-CIBERES (IIS-FJD-CIBERES), Madrid, Spain
2 shared publications Germán Peces-Barba
Respiratory Research Group, Instituto de Investigación Sanitaria - Fundación Jiménez Díaz - CIBERES, Universidad Autónoma de Madrid (IIS-FJD-CIBERES-UAM), Madrid, Spain
1 shared publication- Germán Peces-Barba
Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain
1 shared publication Juan José Díaz-Gil
Respiratory Research Group, Instituto de Investigación Sanitaria - Fundación Jiménez Díaz - CIBERES, Universidad Autónoma de Madrid (IIS-FJD-CIBERES-UAM), Madrid, Spain
1 shared publication- Laura del Puerto-Nevado
Laboratorio de Neumología Experimental, IIS-Fundación Jiménez Díaz, CIBERES, Madrid, España
1 shared publication Nicolás González-Mangado
Respiratory Research Group, Instituto de Investigación Sanitaria - Fundación Jiménez Díaz - CIBERES, Universidad Autónoma de Madrid (IIS-FJD-CIBERES-UAM), Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 17 November 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (11) , e112995
Proliferative Activity of Liver Growth Factor is Associated with an Improvement of Cigarette Smoke-Induced Emphysema in Mice
Cigarette smoke (CS)-induced emphysema is a major component of chronic obstructive pulmonary disease (COPD). COPD treatment is based on the administration of bronchodilators and corticosteroids to control symptoms and exacerbations, however, to date, there are no effective therapies to reverse disease progression. Liver growth factor (LGF) is an albumin-bilirubin complex with mitogenic properties, whose therapeutic effects have previously been reported in a model of emphysema and several rodent models of human disease. To approach the therapeutic effect of LGF in a model of previously established emphysema, morphometric and lung function parameters, matrix metalloproteinase (MMP) activity and the expression of several markers, such as VEGF, PCNA, 3NT and Nrf2, were assessed in air-exposed and CS-exposed C57BL/6J male mice with and without intraperitoneal (i.p.) injection of LGF. CS-exposed mice presented a significant enlargement of alveolar spaces, higher alveolar internal area and loss of lung function that correlated with higher MMP activity, higher expression of 3NT and lower expression of VEGF. CS-exposed mice injected with LGF, showed an amelioration of emphysema and improved lung function, which correlated with lower MMP activity and 3NT expression and higher levels of VEGF, PCNA and Nrf2. Taken together, this study suggests that LGF administration ameliorates CS-induced emphysema, highlights the ability of LGF to promote alveolar cell proliferation and may be a promising strategy to revert COPD progression.
- 17 November 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (11) , e112995
Open AccessProliferative Activity of Liver Growth Factor is Associated with an Improvement of Cigarette Smoke-Induced Emphysema in Mice
Cigarette smoke (CS)-induced emphysema is a major component of chronic obstructive pulmonary disease (COPD). COPD treatment is based on the administration of bronchodilators and corticosteroids to control symptoms and exacerbations, however, to date, there are no effective therapies to reverse disease progression. Liver growth factor (LGF) is an albumin-bilirubin complex with mitogenic properties, whose therapeutic effects have previously been reported in a model of emphysema and several rodent models of human disease. To approach the therapeutic effect of LGF in a model of previously established emphysema, morphometric and lung function parameters, matrix metalloproteinase (MMP) activity and the expression of several markers, such as VEGF, PCNA, 3NT and Nrf2, were assessed in air-exposed and CS-exposed C57BL/6J male mice with and without intraperitoneal (i.p.) injection of LGF. CS-exposed mice presented a significant enlargement of alveolar spaces, higher alveolar internal area and loss of lung function that correlated with higher MMP activity, higher expression of 3NT and lower expression of VEGF. CS-exposed mice injected with LGF, showed an amelioration of emphysema and improved lung function, which correlated with lower MMP activity and 3NT expression and higher levels of VEGF, PCNA and Nrf2. Taken together, this study suggests that LGF administration ameliorates CS-induced emphysema, highlights the ability of LGF to promote alveolar cell proliferation and may be a promising strategy to revert COPD progression.
- 31 December 2010
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 46, 2-7
Papel de la inflamación en la etiopatogenia de la EPOC
- 31 December 2010
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 46, 2-7
Papel de la inflamación en la etiopatogenia de la EPOC